Is Triple Therapy the New Standard for Metastatic Hormone-sensitive Prostate Cancer? - touchONCOLOGY
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis - European Urology Focus
Treatment of Metastatic Prostate Cancer in 2018.,JAMA Oncology - X-MOL
Computed Tomography (CT) and Bone Scans (BS) for Hormone Sensitive Prostate Cancer - YouTube
Oligometastatic cancer: Total Eradication Treatment TET) Trials — Cancer Ecology Center
APCCC 2019: Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer?
Triplet Therapy Has a Place in Metastatic Hormone-Sensitive Prostate Cancer Treatment, But For Whom?
Impact of high-volume disease in Asian population with newly diagnosed metastatic prostate cancer Cheng YT, Hong JH, Lu YC, Pu YS, Huang CY, Huang KH, Liu SP, Chen CH - Urol Sci
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer - eBioMedicine
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
Frontiers | Comparing the Survival Outcomes of Radical Prostatectomy Versus Radiotherapy for Patients With De Novo Metastasis Prostate Cancer: A Population-Based Study
EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial
PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease | Journal of Nuclear Medicine
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl2/AS:947382543974400@1602885008617/Key-findings-hormonal-treatment-combined-with-chemotherapy-in-men-presenting-with_Q320.jpg "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
EAU 2021: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis
Prostate Cancer Review
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? - The Lancet Oncology
Prostate Cancer: Double VS triplet therapy in mHSPC - Urology Cheatsheets
A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer - ScienceDirect
EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial
Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand | Bentham Science
Consultation Report Topic details 1. Summary 2. Background 3. Publication of consultation
Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Cases - Synchronous Low Volume mHSPC
